Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic
- 22 September 2025
- journal article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (11) , 3092-3100
Abstract
Objectives: This study aimed to assess eligibility for long-acting injectable (LAI) cabotegravir/rilpivirine among people with HIV (PWH), identify factors associated with initiation and examine provider prescribing patterns in an urban academic clinic in the USA. Patients and methods: We conducted a retrospective cohort analysis among PWH at the University of Chicago HIV clinic from 1 January 2021 to 31 May 2023. Eligibility criteria for LAI cabotegravir/rilpivirine included HIV-1 RNA <50 copies/mL for ≥3 months, no active hepatitis B, no resistance to rilpivirine or cabotegravir and no treatment failure history. Logistic regression identified factors associated with initiation among eligible PWH as well as prescribing patterns of providers. Results: Of 657 PWH, 413 (63%) were eligible for LAI cabotegravir/rilpivirine. Median age was 45, 33% were women, 84% Black, 70% had permanent housing, 52% employed, 56% on Medicaid, 9% had active substance use and 26% had psychiatric comorbidities. Among those eligible, 64 PWH (15%) initiated LAI cabotegravir/rilpivirine. In multivariate analysis, younger age was the only factor associated with LAI cabotegravir/rilpivirine initiation [OR 0.96, 95% CI (0.94, 0.99), P = 0.01]. Prescribing patterns varied widely among the 13 providers, with initiation rates ranging from 0% to 33% (P < 0.001). Two providers, covering 40% of eligible patients, were responsible for 70% of initiations. Conclusions: In our urban HIV clinic, 63% of PWH were eligible for LAI cabotegravir/rilpivirine, and 15% initiated it within 2.5 years post-approval. Age and provider patterns significantly influenced LAI cabotegravir/rilpivirine uptake. Understanding factors driving LAI cabotegravir/rilpivirine uptake is key to expanding its reach.Keywords
Funding Information
- National Institutes of Health (R01 MH123396)
- National Institute of Allergy and Infectious Diseases (K24 AI167805)
- ANRS
- Maladies Infectieuses Emergentes
- French Society of Infectious Diseases
- SPILF
- Société de Pathologie Infectieuse de Langue Française
This publication has 31 references indexed in Scilit:
- Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United StatesAIDS and Behavior, 2024
- Perspectives of people living with HIV‐1 on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation‐effectiveness studyJournal of the International AIDS Society, 2022
- Perspectives of healthcare providers on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation‐effectiveness study (CUSTOMIZE)Journal of the International AIDS Society, 2022
- Are we ready for long‐acting? A feasibility evaluation of long‐acting cabotegravir–rilpivirine in clinical practiceJournal of Medical Virology, 2022
- Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countriesThe Lancet HIV, 2021
- Real-World Adherence to Antiretroviral Therapy Among HIV-1 Patients Across the United StatesAdvances in Therapy, 2021
- The LAIs Are Coming! Implementation Science Considerations for Long-Acting Injectable Antiretroviral Therapy in the United States: A Scoping ReviewAIDS Research and Human Retroviruses, 2021
- Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infectionAIDS Care, 2020
- Perspectives of injectable long acting antiretroviral therapies for HIV treatment or prevention: understanding potential users’ ambivalencesAIDS Care, 2020
- Current status and prospects of HIV treatmentCurrent Opinion in Virology, 2016